Compare PFS & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFS | SRPT |
|---|---|---|
| Founded | 1839 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2002 | 2000 |
| Metric | PFS | SRPT |
|---|---|---|
| Price | $22.67 | $17.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 29 |
| Target Price | $23.75 | ★ $25.85 |
| AVG Volume (30 Days) | 819.4K | ★ 2.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 112.38 | N/A |
| EPS | 0.61 | ★ 2.88 |
| Revenue | $73,109,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $0.68 | N/A |
| Revenue Next Year | $5.97 | N/A |
| P/E Ratio | $36.85 | ★ $5.88 |
| Revenue Growth | 7.06 | ★ 15.58 |
| 52 Week Low | $16.08 | $10.42 |
| 52 Week High | $23.98 | $25.32 |
| Indicator | PFS | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 54.78 |
| Support Level | $21.52 | $16.67 |
| Resistance Level | $22.86 | $18.16 |
| Average True Range (ATR) | 0.51 | 0.84 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 54.77 | 84.58 |
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.